Navigation Links
FDA approved leukemia drugs shows promise in ovarian cancer cells
Date:11/10/2009

who would respond prior to treatment, personalizing their care.

"We were able to identify markers in the pre-clinical setting that would allow us to predict response to Sprycel," Konecny said. "These may help us in future clinical trials in selecting patients for studies of the drug."

Sprycel is what is known as a "dirty" kinase inhibitor, meaning it inhibits more than one pathway. Konecny said it also inhibits the focal adhesion kinase and ephrin receptor, also associated with ovarian cancer.

The next step, Konecny said, would be to test the drug on women with ovarian cancer in a clinical trial. The tissue of responders would then be analyzed to determine if the Src and other pathways were activated. If that is confirmed, it would further prove that Sprycel could be used to fight ovarian cancer. In studies, women would be screened before entering a trial and only those with Src dependent cancers could be enrolled to provide further evidence, Konecny said, much like the studies of the molecularly targeted breast cancer drug Herceptin enrolled only women who had HER-2 positive disease.

"Herceptin is different because we knew in advance that the only worked in women with HER-2 amplification," he said. "In this case, we don't clearly know that yet. The data reassure us that the drug works where the targets are over-expressed but we need more testing to confirm this."

The tests combining the drug with chemotherapy are significant because chemotherapy currently is the first line treatment for ovarian cancer patients following surgery. Because Sprycel proved to have a synergistic effect when combined with chemotherapy both made the other work better it may be possible to add the targeted therapy as a first line treatment if its efficacy is confirmed in future studies, adding a new tool to an oncologist's arsenal.


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology news :

1. Research approved for Hawaiian military training area
2. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
3. Harris Corporation Adds Broadband Satellite Data Mode to JTRS-Approved Falcon III(R) AN/PRC-117G Multiband Manpack Radio
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. Daisies lead scientists down path to new leukemia drug
7. Gene therapy protocol at UCSD activates immune system in patients with leukemia
8. Two suppressor molecules affect 70 genes in leukemia
9. Tumor-inhibiting protein could be effective in treating leukemia
10. Lab study shows methadone breaks resistance in untreatable forms of leukemia
11. Syracuse University researchers discover new way to attack some forms of leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... The support of peer groups and clinicians ... programs, according to recent University of Georgia research. ... the Athens-Clarke County area determined that role models ... of mothers of infants. , "Mothers who received ... at breastfeeding," said study co-author Alex Anderson, an ...
(Date:8/28/2014)... Aug. 28, 2014  Privacy Advocate and Senior Staff ... Lynch , joins the lineup of biometric and mobile ... Biometrics UnPlugged Executive Summit in Tampa, Florida ... Previously announced speakers include Steven Rahman, Director, Technology and Strategy ... at Experian. The theme of this year,s event is ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of Sports Medicine,s Conference on Integrative Physiology of ... These awards are meant to promote the ... underrepresented groups into the mainstream of the basic ... young scientists at the American College of Sports ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... study has pinpointed a natural ingredient of human blood ... human AIDS, from infecting immune cells and multiplying. The ... of HIV to full-blown AIDS and—because it works in ... the development of another class of drugs in the ...
... of the tumor-suppressor gene Rb2/p130 has demonstrated the ability ... developed into an anti-cancer therapeutic, according to researchers at ... Medicine. , The researchers reported their findings, "A small ... inhibition of cdk2 activity, cell cycle arrest and tumor ...
... special cocoa made to retain naturally occurring compounds called ... brain function and chart the course for future research ... decline and dementia, according to a panel of scientists ... the American Association for the Advancement of Science (AAAS). ...
Cached Biology News:Discovery of an HIV inhibitor in human blood points to new drug class 2Discovery of an HIV inhibitor in human blood points to new drug class 3Small molecule dervived from Rb2/p130 could act as cancer therapeutic 2Flavanols in cocoa may offer benefits to the brain 2Flavanols in cocoa may offer benefits to the brain 3
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... Supplementing their complete line of ... Eppendorf Safe Lock Centrifuge Tubes . This ... quality tubes at an affordable price. Eppendorf Safe ... chemical, medical, pharmaceutical, and life science research and ... able to afford Eppendorf products. , Eppendorf is ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) today announced ... the European Union to pursue CE Marking,the SEPET(TM) ... British,Standards Institute (BSI), one of the leading notified ... effort to obtain a CE Mark for SEPET, ...
... diaDexus, Inc.,today announced the appointment of Fisher HealthCare ... Test for the Hitachi, Hitachi,Roche P-Modular and Olympus chemistry ... was recently cleared by the U.S.,Food & Drug Administration ... chemistry analyzers., The PLAC Test is the only ...
... LA JOLLA, Calif., April 15 DermTech, ... detection of,melanoma and other diseases, will present data ... non-invasive assay that distinguishes melanoma,from benign moles. The ... of Melanoma in Suspicious Pigmented Nevi", shows that ...
Cached Biology Technology:Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 2Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 3Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 4diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test 2diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test 3DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR 2
Assay Diluent, 10 L...
Assay Diluent Trial Pack, 4 x 100 mL...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: